mirikizumab
FDA Approves Omvoh for Moderate to Severe Crohn’s Disease
The FDA has approved mirikizumab as a first-line therapy for moderate to severe Crohn’s disease in adults.
JANUARY 17, 2025
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease
The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...
SEPTEMBER 5, 2024
Equipoise at Risk With Placebo-Controlled Trials
The standard approach to randomized clinical trials for moderate to severe IBD causes harm to participants, ...
MAY 21, 2024
Treating Patients With Inflammatory Bowel Disease and Obesity
An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...
MAY 10, 2024
First-Line Surgery for CD and Possibility of Precision Medicine for UC
This month, Miguel Regueiro, MD, examines whether surgery should be the first-line treatment for some with ...
FEBRUARY 16, 2024
2 Exciting New FDA Approvals For Ulcerative Colitis Treatment
In this month’s The Regueiro Report, I’d like to highlight two exciting FDA approvals for moderately to ...
JANUARY 23, 2024
Miguel Regueiro, MD, Highlights Noteworthy IBD Research at ACG 2023
Miguel Regueiro, MD, sat down with us to talk about some of his favorite inflammatory bowel disease research ...
JANUARY 5, 2024
FDA Approves Mirikizumab for Ulcerative Colitis
The FDA has approved mirikizumab-mrkz (Omvoh, Lilly) for the treatment of moderate to severe ulcerative colitis in ...
OCTOBER 27, 2023
Mirikizumab Has QOL Benefits in Analysis of LUCENT UC Data
A new analysis of the pivotal phase 3 trials shows that mirikizumab improved quality of life in patients with ...
MAY 15, 2023
